The investment seeks capital appreciation... Show more
The Corgi Longevity Consumer ETF (YUNG) seeks capital appreciation through an actively managed portfolio of companies materially involved in consumer-oriented products and services positioned to benefit from aging demographics and the spending preferences of older consumers. The adviser, Corgi Strategies, LLC, emphasizes businesses it believes can extend healthspan and benefit lifestyle and services categories tied to an aging population.
The fund is non-diversified and semi-transparent, invests at least 80% of net assets in its target theme, and is listed on the Cboe BZX Exchange. It launched in May 2026 and carries a net expense ratio of 0.35%. With total assets under management (AUM) of roughly $1 million, the ETF remains a small, early-stage vehicle, and its secondary-market trading volume is thin.
Portfolio concentration is notable. Eli Lilly (LLY) is by far the largest holding at about 14% of assets, followed by Welltower (WELL), Medtronic (MDT), Booking Holdings (BKNG), and Humana (HUM). Travel and leisure names such as Delta Air Lines (DAL), Marriott (MAR), Royal Caribbean (RCL), and Hilton (HLT) also feature prominently. Healthcare accounts for the largest sector allocation, with consumer discretionary, real estate, and industrials completing the bulk of exposure.
The longevity theme sits at the intersection of two durable structural forces: an aging global population and rising demand for products and services that preserve quality of life. Within healthcare, pharmaceutical innovation — particularly in weight management and cardiometabolic treatments — has reshaped investor expectations, while senior housing and healthcare real estate benefit from demographic-driven occupancy trends.
The consumer discretionary sleeve, anchored by travel, hospitality, and cruise operators, reflects a related thesis: older consumers represent an expanding share of leisure spending. This positioning makes the fund sensitive to consumer confidence, airfare and occupancy trends, and discretionary spending cycles.
Macroeconomic conditions remain an important backdrop. Interest-rate expectations influence both healthcare real estate valuations and consumer borrowing costs, while inflation trends affect household budgets and travel demand. Because the portfolio is heavily weighted toward U.S. large-cap names, broader equity-market sentiment and sector rotation between growth and value styles also shape its behavior.
YUNG's recent price action has been range-bound rather than trend-driven. After trading near the $29 level in late summer, the fund pulled back into the mid-$26 range during September before recovering to approximately $29 by early November — a rebound of roughly 9% over the trailing month and a roughly flat result over the broader three-month window. This pattern is consistent with a small, thinly traded ETF where individual-session price moves can be amplified by low liquidity.
The recovery largely tracked strength in the fund's largest position. Eli Lilly's weight means its share-price moves have an outsized effect on the portfolio's net asset value (NAV). Meanwhile, steady performance across travel and hospitality holdings and healthcare real estate provided additional support, even as the healthcare-heavy allocation exposed the fund to periodic sector-specific volatility.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. It is designed to surface trending securities, breakout candidates, and new trading opportunities more efficiently than manual screening. For investors monitoring themes such as longevity, healthcare, and consumer travel, the screener offers a structured way to compare candidates and refine a watchlist. Explore the AI Screener to identify opportunities aligned with your own investment framework.
Several structural factors are likely to influence YUNG over the remainder of 2026. In healthcare, the trajectory of cardiometabolic and longevity-oriented drug franchises — particularly Eli Lilly's pipeline — will remain a dominant driver given the fund's concentrated exposure. Regulatory developments around drug pricing and reimbursement could also affect sentiment.
Within real estate, interest-rate expectations will be pivotal for senior-housing and healthcare REIT valuations, while demographic tailwinds should continue to support long-term occupancy demand. For the consumer discretionary sleeve, travel demand, airfare pricing, and consumer confidence will set the tone for hospitality and airline holdings.
Investors should also monitor the fund's own growth trajectory. As a small, recently launched vehicle, changes in AUM, trading liquidity, and any adjustments to portfolio construction could influence how closely its market price tracks its NAV. Sustained inflation, shifting Federal Reserve policy, and broader sector rotation between healthcare, discretionary, and real estate will remain key cross-currents. None of these observations constitute a forecast of future returns; they simply frame the themes most likely to shape the fund's behavior in the months ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
YUNG broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +1.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where YUNG advanced for three days, in 2 of 3 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 12 of 16 cases where YUNG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows